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Abstract
Purpose of review—This review summarizes the development and implementation of a large
clinical trial, HIV Prevention Trials Network (HPTN) 052, whose initial results were recently
presented and published.
Recent findings—A randomized, clinical trial demonstrated that antiretroviral therapy reduces
the sexual transmission of HIV in HIV-serodiscordant couples by more than 96%. The logistical
challenges in preparing for and conducting such a trial were considerable.
Summary—HPTN 052 required many years of preparation, considerable collaboration between
National Institute of Health and six pharmaceutical companies, and careful ongoing consideration
of a large number of ethical issues. HPTN 052 revealed the magnitude of benefit when using
antiretroviral therapy to prevent the transmission of HIV, and served as proof of a concept. The
results have proven central to the development of new global HIV-prevention efforts.
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INTRODUCTION
The use of antiretroviral therapy (ART) for the treatment of HIV-1 is currently one of the
most popular ideas to reduce transmission of HIV [1 – 8]. The strategy has generated a
plethora of mathematical models that, for the most part, predict success [9–14,15*,
16,17,18**,19 – 21], and several ecological studies that argue that the prevention benefit of
ART can already be seen in a few communities where ART usage is high [22,23,24*,25*].
These public health aspirations are truly important. However, policies favoring the use of
treatment as prevention have been rapidly moving forward in the absence of a critical piece
of information: the degree to which ART actually prevents the transmission of HIV and the
durability of the effect(s) of ART for this purpose. The purpose of this article is to review
briefly the development and results of a single, multicenter, Phase III, clinical trial designed
to ask whether the treatment of HIV infection also prevents the sexual transmission of
HIV-1 in HIV-serodiscordant couples.
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In 2000, researchers from the Rakai (Uganda) project [26] reported that the concentration of
HIV in blood plasma could be correlated with HIV transmission probability in HIV-
serodiscordant couples. The study concluded that the risk of transmission of HIV with less
than 1500 copies of HIV RNA is negligible.
Prior to the Rakai study, however, several reports showed that HIV can also be recovered in
genital secretions, as would be predicted based on the sexual transmission of the virus. With
the development of the first antiretroviral agent – azidothymidine – interest surfaced in
reducing replication of HIV in the genital tract with ART [27]. Many groups working on this
problem were focused on developing “treatment as prevention'. Indeed, in 1997, in a study
from our group on this matter, we stated, `… antiretroviral therapy, by decreasing levels of
HIV-1 in semen, may lower the infectious inoculum of treated men and possibly reduce the
likelihood of sexual transmission to uninfected partners (p. 60) [28].
This work led to a series of reports about the concentration of HIV in semen using
quantitative culture [29 – 31] and development of a PCR technique for more accurate
measurement [32]. With these tools, studies demonstrated that ART reduced the
concentration of HIV in both semen [33, 34] and female genital secretions [35]. Evidence
also emerged that antiretroviral drugs penetrate the male and female genital tract with
different efficiency, [36, 37] helping to explain the sexual transmission of resistant viruses
[38 – 41].
HPTN 052: TRIAL DESIGN
Consistent with the Rakai study [26], other observational studies supported the critical
importance of viral load in HIV transmission [42]. However, blood viral load never
correlates perfectly with genital tract HIV [43 – 45]. In addition, the exact mode of HIV
transmission – whether from cell-free or cell- bound virus remains obscure. Although
inductive logic suggested that ART that suppresses HIV replication should also reduce HIV
transmission, the magnitude and durability of such an effect could not be determined
without empirical evidence. In 2000, the National Institute of Allergy and Infectious
Diseases/National Institutes of Health (NIAID/NIH)-sponsored HIV Prevention Trials
Network (HPTN) approved the development of a protocol to study the use of ART to reduce
HIV in blood and genital secretions and, thus, prevent the sexual transmission of HIV in
HIV-serodiscordant couples.
After careful consideration, the only plausible and ethical design was to randomize HIV-
serodiscordant couples into two study arms: early vs. delayed therapy. In the early arm, ART
would be offered at CD4 cell counts higher than when ART was recommended by the WHO
in the respective countries where the study would take place. In the delayed arm, ART
would be offered when the CD4 cell count fell to the general standard of care, that is, below
200 cells/ml in the pilot phase of the study, modified to at or below 250 cells/mm3 in the full
trial (Fig. 1). Through a detailed statistical plan, including modeling of the timeframe for
both the decline of CD4 cell counts and potential trans- mission events, it was determined
that 1750 participants with HIV (and CD4 cell counts between 300 and 500 cells/ml in the
pilot phase, and 350 – 550 cells/ml in the full study) and their HIV-negative partners would
be needed to answer the primary objective, which was to compare the rates of HIV infection
between the two arms (Fig. 1). As already noted, the CD4 cell count inclusion criterion
changed over the course of the study. Thirteen clinical sites worldwide participated (nine
initially, and four more in 2009 in order to increase the rate of enrollment), starting with a
pilot phase in 2005, followed by the initiation of the full study in 2007. A list of the sites, the
number of couples enrolled at each site, and the enrollment inclusion/exclusion criteria are
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shown in Tables 1 and 2 [46**]. The current version of the protocol is available at http://
www.hptn.org.
HPTN 052: PRE-IMPLEMENTATION REQUIREMENTS
Having designed a plausible trial, the study faced two difficult challenges. First, NIAID
policy in the early 2000s required that US pharmaceutical companies donate drugs for use in
the study. We calculated that 1750 discordant couples would be recruited and followed on-
study until the last couple completed 5 years of study follow-up, and the statistical plan
assumed that every HIV-infected person in the delayed arm would eventually be placed on
ART (statistical plan available in the protocol at http://www.hptn.org). These assumptions
led to the recognition that large amounts of drug were required to conduct the study
successfully, no company would receive actual benefit from the trial because no treatment
comparisons were planned, and multiple anti-retroviral combinations would be required for
first- and second-line therapy. Through an iterative process, we were able to establish a
collaborative agreement with each of the companies listed in Table 3 to provide their drug
products. Second, our collaborating partners in the NIH-sponsored AIDS Clinical Trials
Group (ACTG) raised concerns that subjects with low CD4 cell count screening out of
HPTN 052 required an option for treatment. This finding led to the development and
implementation of an inter- national ACTG protocol (ACTG 5175), launched at all
participating HPTN 052 sites at the time the HPTN 052 study began [47,48].
Other pre-study implementation requirements included the development of detailed clinical
and counseling materials. Regional trainings were conducted over the course of a year on the
clinical management of ART and couples risk-reduction counseling. In addition, on-site
training on the protocol requirements was conducted at all 13 sites over the course of 2
years.
HPTN 052: ETHICS AND EQUIPOISE
The ethical considerations related to HPTN 052 are substantial and will be the subject of a
separate detailed report (Cohen and Sugarman, unpublished). In brief, the initial idea of the
study met with three criticisms: offering ART could be coercive due to a lack of availability
of ART to the general population in the majority of the countries participating in the study,
ART should not be offered at high CD4 cell counts (i.e., above current guidelines), and ART
would undermine prevention counseling – the proven intervention – resulting in negative
risk compensation behaviors. These concerns are entirely valid. The informed consent
process was used to define alternative strategies for potential study subjects to obtain ART
at a CD4 cell count consistent with local country guidelines and to describe the potential
costs and benefits of earlier ART. Repeated couples counseling during the course of the
study was used to reduce increased risk-taking behavior. Indeed, the trial was designed to
study the potential benefit of risk-reduction counseling through the measurement of sexual
behavior and condom use.
Other concerns arose as the trial was moving forward, including the issue of separation of
the role of an investigator vs. their role as a clinical care provider. Because healthcare
workers are a rare commodity in countries with a heavy HIV disease bur- den, the
participants and caregivers might find it difficult to separate clinical care from research. This
problem is sometimes referred to as the `therapeutic misconception' [49]. To mitigate this
conflict of interest among the investigators, an `on-call' clinical management team was
established, charged with advising all sites on general clinical management and complicated
clinical cases within the parameters dictated by the protocol.
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Evolving science created yet another challenge for the study team. With increased interest in
HIV prevention, a large number of modeling studies [8] and observational studies
[50,51,52*,53] purported to resolve both the value of ART for prevention and the `when to
start ART' question [54*,55,56,57*]. These reports forced consideration of the equipoise
balance required for the trial to proceed [58]. Ultimately, observational treatment studies led
to changes in WHO [59] and other guidelines, [60] leading to both practical and ethical
concerns about HPTN 052. At the same time, the Swiss AIDS Commission concluded that
the benefits of ART had been resolved and offered the `Swiss Statement' to make this point
[61]. However, the issues considered (by some) `resolved' by the observational trials were
being directly addressed by HPTN 052. The weight of evidence for both early treatment and
ART for prevention has been summarized in two Cochrane reviews [62*,63].
Publication of the Comprehensive International Program of Research on AIDS (CIPRA)
Haiti study [64*] had additional and important effects on HPTN 052 because of concern that
clinical equipoise had been breached, favoring earlier ART. The CIPRA Haiti study was
designed to compare early vs. delayed ART. In this study, however, the subjects were
enrolled with a mean CD4 cell count of 287 cells/ml, and the delayed arm received ART at a
CD4 cell count of 160 cells/ml, which were far different degrees of immunosuppression than
studied in HPTN 052.
The results of the CIPRA Haiti study led to an urgent ad-hoc meeting of the Data and Safety
Monitoring Board (DSMB) overseeing HPTN 052 in July 2009. The DSMB recommended
that HPTN 052 continue without modification to the study design. In November 2009, WHO
updated their guidelines for the initiation of ART to at or below a CD4 cell count of 350
cells/ml [59] for the general population. We communicated changes in WHO treatment
guidelines to all study participants, along with information about the provision of ART
avail- able in their local setting. The study itself underwent no changes, as it was designed
specifically to provide `Level 1 evidence' for policy changes predicated on less robust
results.
THE EVENTUAL HPTN 052 TRIAL: A SUMMARY
HPTN 052 began in a pilot phase in April 2005 and enrolled 1763 HIV-serodiscordant
couples, the vast majority of which (97%) were heterosexual. The study was conducted at 13
sites across Africa, Asia, and the Americas. During a regularly scheduled review in April
2011, the study's DSMB recommended that current results be released to the public as soon
as possible. The primary results of HPTN 052 have been published [46**]. For each
transmission event, genetic analysis was conducted to determine whether the event was
`linked', meaning that the virus had been transmitted between the members of the enrolled
couple, or `unlinked', meaning that the new infection had been acquired outside of the
primary relationship. Among the 877 couples in the delayed ART group, 27 linked HIV
transmissions occurred. This finding was in contrast to only one linked transmission that
occurred in the immediate ART group. This difference was highly statistically significant.
At least 10 unlinked transmission events also occurred, suggesting that the couples
counseling provided through the study was not entirely effective. Clinical benefit was also
observed in participants receiving early ART. HPTN 052 provides unambiguous proof that
ART can stop the transmission of HIV.
HPTN 052: THE WAY FORWARD
The HPTN 052 study is still ongoing. Given the current results of the trial, participants on
the delayed ART arm are being offered ART. With the continuation of the study, we will be
able to reliably answer the other important question the study was designed to answer: is the
reduction of sexual transmission of HIV by ART durable?
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HPTN 052 is a complicated and challenging study design to prove a single concept that
treating HIV- infected people with effective ART will render them less contagious. This
idea is central to the `test and treat' strategy [6]. The results of the study were met with great
enthusiasm upon their release in May 2011, and at the 6th International AIDS Society HIV
Pathogenesis Meeting in Rome, July 2011. HPTN 052 represents a nearly 20-year
investment in marrying exceptionally strong biological plausibility to a clinical trial. The
findings of HPTN 052 were heralded as a `game changer', [65] and became the foundation
for The Economist's `The End of AIDS?' issue [66]. The goal now is to determine whether
ART can be used so broadly and so effectively as to reduce the spread of HIV within a
population. At least two community randomized trials that employ ART as their cornerstone
are planned [6], and the results should determine the true benefit of this provocative and
very effective intervention.
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Table 1
Enrollment of HIV-Serodiscordant Couples by Site
Site Enrollment (Number of Couples)
Porto Alegre, Brazil 90
Rio de Janeiro, Brazil 186
Boston, MA, USA 2
Chennai, India 250
Pune, India 175






Johannesburg, South Africa 46
Soweto, South Africa 50
Total Enrollment 1763
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Table 2A
HPTN 052 Study Inclusion Criteria
Couple Index Case (HIV-infected) Partner (HIV-uninfected)
• Men and women age ≥ 18 years.
• Willing to disclose HIV test results to
partner.
• Not intending to relocate out of the area
for the duration of study participation and
does not have a job or other obligations
that may require long absences from the
area.
• Plans to maintain a sexual relationship
with the person who is enrolled in the
study with them.
• Reports having sex (vaginal or anal) with
partner at least 3 times in the last 3 months
(reports separately and not in front of each
other).
• Positive HIV serology obtained within
60 days prior to enrollment
• Willing to be randomized if pregnant
or breast feeding
■ CD4+ cell count of 350–550 cells/
mm3
■ Hemoglobin ≥ 7.5 g/dL; platelet
count ≥50,000/μL; AST (SGOT),
ALT (SGPT), and alkaline
phosphatase ≤ 5 × ULN; total
bilirubin ≤ 2.5 × ULN; calculated
creatinine clearance ≥ 60 mL/min;
absolute neutrophil count ≥ 750 mm3
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Table 2B
HPTN 052 Study Exclusion Criteria
Couple Index Case (HIV-infected)
• Reports a history of injection drug use
within the last five years.
• Previous and/or current participant in
an HIV vaccine study.
• Any condition that, in the opinion of
the site investigator, would make
participation in the study unsafe,
complicate interpretation of study
outcome data, or otherwise interfere
with achieving the study objectives.
• Incarceration in a correctional facility,
prison, or jail; and involuntary
incarceration in a medical facility for
psychiatric or physical (e.g. infectious
disease) illness
• Current or previous AIDS-defining illness
• Current or previous use of any ART drugs (some exceptions apply)
• Documented or suspected acute hepatitis within 30 days prior to enrollment,
irrespective of AST (SGOT) and ALT (SGPT) values.
• Acute therapy for serious medical illnesses, in the opinion of the site
investigator, within 14 days prior to enrollment. Candidates with chronic,
acute, or recurrent infections that are serious, in the opinion of the site
investigator, who must continue with chronic (maintenance) therapy (e.g.,
TB), must have completed at least 14 days of therapy prior to study entry and
be clinically stable.
• Radiation therapy or systemic chemotherapy within 45 days prior to
enrollment.NOTE:Anticipated need for systemic chemotherapy while on
study is not permitted.
• Any immunomodulator or other investigational therapy within 30 days prior
to enrollment.
• Active drug or alcohol use or dependence that, in the opinion of the site
investigator, would interfere with adherence to study requirements.
• Vomiting or inability to swallow medications due to an active, pre-existing
condition that prevents adequate swallowing and absorption of study
medication.
• Need for a prohibited medication
• Allergy/sensitivity to any study drugs or their formulations.
Note: There are no explicit exclusion criteria for HlV-uninfected participants (partners)
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Table 3
Antiretroviral Drug Donations for HPTN 052
Pharmaceutical Company Donated Antiretroviral Drug
Abbott Laboratories Kaletra®/Aluvia® (lopinavir/ritonavir)
Ritonavir
Boehringer-lngelheim Pharmaceuticals, Inc. (BI) Nevirapine








Merck & Co., Inc. efavirenz (non-US sites)
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